Mersana Therapeutics Inc (NASDAQ: MRSN) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months.
JPMorgan analyst Jessica Fye downgraded Mersana from Neutral to Underweight and withdrew the previous $10 price target.
With $160 million pro forma cash and an enterprise value of $55 million, Mersana shares already reflect substantial market skepticism, Fye said in the Monday downgrade note.
Upcoming data releases are unlikely to reverse the prevailing sentiment, the analyst said.
Fye said she sees sufficient runway for Mersana to generate expansion cohort data for its lead asset XMT-1536, with the initial dose escalation readout in January signaling activity.
" ... Confirmation of durable benefit is what we think will be needed to drive the market to ascribe more value to this asset."
Updated dose escalation data due in the second quarter — with a mix of doses, tumor types and NaPi2b expression levels — is unlikely to answer the question, let alone provide a strong read on the potential for success in future studies, the analyst said.
The Price Action
Mersana shares were down 0.66 percent at $4.49 at the time of publication Monday.
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs
Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts
Latest Ratings for MRSN
|Mar 2019||JP Morgan||Downgrades||Neutral||Underweight|
|Jul 2018||Leerink Swann||Downgrades||Overweight||Market Perform|
|May 2018||Baird||Initiates Coverage On||Outperform|
View More Analyst Ratings for MRSN
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings
- The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.